hydromethylthionine mesylate; leucomethylene blue dimesylate (HMTM)

Indications

• experimental oral agent for prevention of Alzheimer's disease in elderly with mild cognitive impairment

* improves cognition over 18 months in elderly with mild cognitive impairment

Dosage

• 16 mg PO QD

Adverse effects

• urine discoloration

Mechanism of action

• experimental oral tau aggregation inhibitor
• struturally related to methylene blue
• 93% reduction of plasma neurofilament light chain over 12 months
• attenuates increase in plasma ptau181

More general terms

• pigment
• tau aggregation inhibitor

Additional terms

• methylene blue; methylthioninium chloride (Provablue, MTC)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60150609